利用自动骨减影软件对乳腺癌患者骨盆进行纵向CT监测
本研究回顾性纳入33例乳腺癌患者共143次标准化基线与随访CT,采用新型骨减影软件生成骨减影图并与常规CT判读比较。骨减影图使9/33(8.1%)患者的分级改为进展性疾病,并额外检出123处新发或增大的硬化性转移灶和32处新发溶骨性转移灶,基于病灶的敏感度98.7%、特异度79.5%、准确率94.5%。作者结论认为纵向骨减影图提高了乳腺癌骨转移CT诊断的准确性和效率。
要点
- 骨减影图在9/33(8.1%)患者中使疗效分级改为进展性疾病。
- 骨减影图较常规CT额外检出123处新发或增大的硬化性及32处新发溶骨性转移灶。
- 基于病灶的敏感度98.7%、特异度79.5%、准确率94.5%,观察者间一致性良好(κ=0.80;P=0.077)。
核心结论
- 作者结论认为纵向骨减影图提高了乳腺癌骨转移CT诊断的准确性和效率。
研究设计与样本
- 回顾性数据评估,经机构审查委员会批准,纳入33例连续乳腺癌患者(31例女性、2例男性;平均年龄59.13±12.68岁;范围32-81岁)。
- 患者于2014年2月至2016年6月间接受143次标准化基线与随访CT检查。
- 将骨转移灶分为溶骨性、硬化性和混合性骨病灶。
- 任何已知硬化性病灶内新出现的骨质溶解和原有硬化性病灶增大视为进展性疾病(PD),无变化归为稳定性疾病(SD)。
- 软件生成的自动骨减影图与常规CT判读的轴位5-mm及冠状位1-mm重组图像进行比较,并用感兴趣区测量量化新病灶,结果经临床和CT随访验证,同时评估阅片时间。
关键影像表现/征象
- 基线时17/33(51%)患者存在骨转移(9例硬化性、2例溶骨性、6例混合性)。
- 与常规CT评估相比,骨减影图在23/33(30.9%)次检查中检出123处新发或增大的硬化性转移灶和32处新发溶骨性转移灶。
- 所有患者新发骨病灶(硬化性或溶骨性)的平均衰减值显著升高或降低(P<0.01)。
- 进展性疾病患者无明确转移病灶的骨盆区域骨衰减值显著升高(P=0.019),而稳定性疾病患者无变化(P=0.076)。
- 骨减影图的阅片时间较5-mm轴位图像显著更快(P<0.001)。
诊断标准与关键数值
- 基于病灶的敏感度98.7%、特异度79.5%、准确率94.5%、阳性预测值95.1%、阴性预测值94.5%。
- 观察者间一致性良好(κ=0.80;P=0.077)。
- 进展性疾病定义为已知硬化性病灶内新出现骨质溶解或原有硬化性病灶增大,无变化为稳定性疾病。
临床应用与阅片要点
- 骨减影图较常规CT使9/33(8.1%)患者疗效分级改为进展性疾病,阅片时需对照减影图与常规图像综合判断。
- 减影图可突出显示常规CT上易遗漏的新发或增大的硬化性及溶骨性病灶,并缩短阅片时间。
- 进展性疾病患者无明确转移灶的骨盆区域骨衰减值也显著升高(P=0.019),判读时需留意背景骨衰减变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to optimize computed tomography (CT) surveillance of skeletal metastases in patients with breast cancer through the use of osseous subtraction maps between baseline and follow-up examinations created by a novel software algorithm. The new postprocessing algorithm segments the original bone followed by image intensity-based rigid alignment creating gray-shaded maps that highlight focal or diffuse loss or increase in bone attenuation.
MATERIALS AND METHODS: Institutional review board was obtained for this retrospective data evaluation. A total of 33 consecutive patients (31 female; 2 male; mean age, 59.13 ± 12.68 years; range, 32-81 years) with breast cancer were included, who underwent 143 standardized baseline and follow-up CT examinations between February 2014 and June 2016. We classified bone metastases into lytic, sclerotic, and mixed osseous lesions. Any new osteolysis inside a known sclerotic lesion and enlargement of pre-existing sclerotic lesions were considered to represent progressive disease (PD), whereas no change was classified as stable disease (SD). Results were compared additionally with the course of the disease considering the entire skeleton and other involved organs. Software-created automated bone subtraction maps were compared with conventional CT interpretations of axial 5-mm and coronal 1-mm reformatted images. Region of interest measurements were used to quantify new lesions. Results were validated by clinical and CT follow-up. Reading time was evaluated.
RESULTS: Skeletal metastases were present in 17/33 (51%) patients (9 sclerotic, 2 lytic, 6 mixed) at baseline. The use of bone subtraction maps resulted in an overall change of response classification into PD in 9/33 (8.1%) patients. Compared with conventional CT evaluation, the bone subtraction maps disclosed 123 new or enlarging sclerotic and 32 new lytic metastases in 23/33 (30.9%) examinations. Mean attenuation of new bone lesions (sclerotic or lytic) significantly increased or decreased (P < 0.01) in all patients. Bone attenuation in pelvic areas without evident metastatic disease significantly increased in patients with PD (P = 0.019), whereas there was no change in SD (P = 0.076). Lesion-based sensitivity, specificity, accuracy, positive predictive values, and negative predictive values were 98.7%, 79.5%, 94.5%, 95.1%, and 94.5%, respectively. Interobserver agreement was good (κ = 0.80; P = 0.077). Reading time was significantly faster for the bone subtraction maps versus 5-mm axial images (P < 0.001).
CONCLUSIONS: Longitudinal bone subtraction maps increase the accuracy and efficiency of CT diagnosis of skeletal metastases in patients with breast cancer.
引用
- Horger M, Thaiss WM, Wiesinger B, et al. Longitudinal Computed Tomography Monitoring of Pelvic Bones in Patients With Breast Cancer Using Automated Bone Subtraction Software. Invest Radiol. 2017. PMID: 28002240. doi:10.1097/RLI.0000000000000343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。